Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEIIa)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02773524
Recruitment Status : Active, not recruiting
First Posted : May 16, 2016
Last Update Posted : January 13, 2022
Sponsor:
Collaborators:
Canadian Cancer Trials Group
Academic and Community Cancer Research United
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Australasian Gastro-Intestinal Trials Group

Brief Summary:
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)

Condition or disease Intervention/treatment Phase
Gastro-Oesophageal Cancer Drug: Regorafenib Other: Placebo Phase 3

Detailed Description:

Purpose:

The purpose of this Phase III study is to determine if regorafenib improves overall survival in patients with Advanced Gastro-Oesophageal Carcinoma.

Who is it for:

You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with advanced (metastatic or locally recurrent) Gastro-Oesophageal Carcinoma which has not responded to a minimum of 2 lines of prior anti-cancer therapy.

Trial Details:

Participants will be randomly (by chance) allocated to one of two groups: regorafenib or placebo in 2:1 ratio respectively and will not be aware of their group allocation. Regorafenib or matching placebo will be self-administered by participants orally once daily on days 1-21 of each 28 days cycle. Treatment will continue until disease progression or prohibitive toxicity. Participants will be followed up every 2-4 weeks in order to evaluate their progress on the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Actual Study Start Date : November 2016
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Regorafenib

Arm Intervention/treatment
Experimental: Regorafenib
Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
Drug: Regorafenib
Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
Other Name: Stivarga

Placebo Comparator: Placebo
Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
Other: Placebo
Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.




Primary Outcome Measures :
  1. Overall Survival [ Time Frame: From time of patient randomisation until date last known alive (up to 12 months following end of treatment). ]
    The interval from the date of randomisation to date of death from any cause, or the date last known alive.


Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: From time of patient randomisation until first evidence of disease progression or death (up to 12 months following randomisation). ]
    The interval from the date of randomisation to the date of first evidence of disease progression or death, whichever occurs first.

  2. Objective Tumour Response Rate [ Time Frame: From time of patient randomisation until evidence of complete or partial response (up to 12 months following randomisation). ]
    The OTRR will be calculated by summing the number of participants in a given arm that are assessed as having a complete or partial response (as per RECIST criteria), and dividing this by the total number of participants in the corresponding arm of the analysis set.

  3. Evaluation of health states experienced by participants [ Time Frame: From time of commencement of treatment until first evidence of disease progression (up to 12 months following commencement of treatment). ]
    Questionnaire used to assess quality of life

  4. Rates of Adverse Events [ Time Frame: From time dose of study treatment until 30 days after last dose of study treatment ]
    A descriptive analysis of the adverse events (AE) data will be prepared for participants in the safety population. The number and percentage of participants who experience AEs will be tabulated according to CTCAE term/category, grade, and seriousness.


Other Outcome Measures:
  1. Identification of tumour markers to that predict treatment outcomes for AGOC [ Time Frame: Up to 24 months following close of recruitment. ]
    Biomarker assessment, CTC DNA assessment to predict whether treatment for AGOC is efficacious

  2. Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts. [ Time Frame: Up to 24 months following close of recruitment. ]
    Evaluation of regorafenib Maximum Plasma Concentration [Cmax] in patients from either Asia or ROW to assess whether genetic factors aide/hinder metabolic rate of consumption of regorafenib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer which:

    1. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and
    2. is of adenocarcinoma or undifferentiated carcinoma histology , and
    3. is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrolment; and
    4. has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue.

      Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment.

    5. HER2-positive participants must have received trastuzumab.
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  3. Ability to swallow oral medication.
  4. Adequate bone marrow function (Platelets ≥100x109/L; Absolute Neutrophil Count (ANC) ≥1.5x109/L and Haemoglobin ≥ 9.0g/dL).
  5. Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine ≤1.5 x Upper Limit of Normal (ULN).
  6. Adequate liver function (Serum total bilirubin ≤1.5 x ULN, and INR ≤ 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)). Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists.
  7. Adequate cardiac function (Left Ventricular Ejection Fraction (LVEF) ≥ 50% or above the lower limit of normal (LLN) for the Institution (whichever is lower). Cardiac function should be assessed within 3 months prior to randomisation, but after completion of any anthracycline-containing chemotherapy.
  8. Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up.
  9. Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday).
  10. Signed, written informed consent.

Exclusion Criteria

  1. Known allergy to the investigational product drug class or excipients in the regorafenib.
  2. Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management).
  3. Participants with known, uncontrolled malabsorption syndromes.
  4. Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and ramucirumab) are permitted.
  5. Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy.
  6. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation.
  7. Concurrent treatment with strong CYP3A4 inhibitors or inducers.
  8. Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to< Grade 2 according to CTCAE V4.03.
  9. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization.
  10. Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization.
  11. Venous thrombotic events and pulmonary embolism within 3 months prior to randomization.
  12. Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v4.03 within 4 weeks prior to randomization.
  13. Non-healing wound, ulcer, or bone fracture.
  14. Interstitial lung disease with ongoing signs and symptoms.
  15. Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed.
  16. Persistent proteinuria of ≥ Grade 3 according to CTCAE v4.03 (equivalent to > 3.5g of protein over 24 hours, measured on either a random specimen or 24 hour collection).
  17. Uncontrolled metastatic disease to the central nervous system. To be eligible, CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time.
  18. History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study:

    1. curatively treated cervical carcinoma in situ,
    2. non-melanomatous carcinoma of the skin,
    3. superficial bladder tumours (T1a [Non-invasive tumour], and Tis[Carcinoma in situ]),
    4. treated thyroid papillary cancer
  19. Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
  20. Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol.
  21. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a barrier method of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02773524


Locations
Hide Hide 60 study locations
Layout table for location information
United States, Arizona
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85054
United States, California
USC Norris
Los Angeles, California, United States, 90001
United States, Illinois
Carle Cancer Center NCI Community Oncology Research Program
Urbana, Illinois, United States, 61801
United States, Virginia
Bon Secours Cancer Institute
Midlothian, Virginia, United States, 76065
Australia, Australian Capital Territory
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Australia, New South Wales
Border Medical Oncology
Albury, New South Wales, Australia, 2640
Monash Medical Centre
Clayton, New South Wales, Australia, 3168
Coffs Harbour Health Campus
Coffs Harbour, New South Wales, Australia, 2450
Concord Repatriation General Hospital
Concord, New South Wales, Australia, 2139
St Vincent's Public Hospital
Darlinghurst, New South Wales, Australia, 2010
Gosford Hospital
Gosford, New South Wales, Australia, 2250
St George Hospital
Kogarah, New South Wales, Australia, 2217
Newcastle Private Hospital
New Lambton Heights, New South Wales, Australia, 2035
Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia, 2444
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
The Tweed Hospital
Tweed Heads, New South Wales, Australia, 2485
Ballarat Oncology and Haematology Services
Wendouree, New South Wales, Australia, 3355
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, Northern Territory
Royal Darwin Hospital
Tiwi, Northern Territory, Australia, 0810
Australia, Queensland
The Townsville Hospital
Douglas, Queensland, Australia, 4814
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia, 4029
Sunshine Coast University Hospital
Sunshine Coast, Queensland, Australia, 4560
Australia, South Australia
Ashford Cancer Centre Research
Ashford, South Australia, Australia, 5035
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia, 5011
Australia, Tasmania
Royal Hobart Hospital
Hobart, Tasmania, Australia, 700
Australia, Victoria
Austin Hospital
Heidelberg, Victoria, Australia, 3084
Australia, Western Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
St John of God Hospital Subiaco
Subiaco, Western Australia, Australia, 6008
Canada
PEI Cancer Treatment Centre, Queen Elizabeth Hospital
Charlottetown, Canada
Queen Elizabeth II Health Sciences Centre
Nova Scotia, Canada
Ottawa Hospital Research Institute
Ottawa, Canada
The Research Institute of the McGill University Health Centre
Québec, Canada
Allan Blair Cancer Centre
Regina, Canada
Saskatoon Cancer Centre
Saskatoon, Canada
University Health Network Princess Margaret Cancer Centre
Toronto, Canada
Japan
National Cancer Centre Hospital East
Chiba, Kashiwa, Japan
Hokkaido University Hospital
Sapporo, Kita, Japan
Korea, Republic of
Hallym University Sacred Heart Hospital
Anyang, Korea, Republic of
Dong-A University Hospital
Busan, Korea, Republic of
Chonbuk National University Hospital
Jeonju, Korea, Republic of
Gyeongsang National University Hospital
Jinju, Korea, Republic of
Chung-Ang University Hospital
Seoul, Korea, Republic of
Korea University Anam Hospital
Seoul, Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of
Seoul National University Bundang Hospital
Seoul, Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
SMG-SNU Boramae Medical Center
Seoul, Korea, Republic of
The Catholic University of Korea - Seoul St. Mary's Hospital
Seoul, Korea, Republic of
The Catholic University of Korea - Yeouido St. Mary's Hospital
Seoul, Korea, Republic of
Yonsei University Health System - Gangnam Severance Hospital
Seoul, Korea, Republic of
Yonsei University Health System - Severance Hospital
Seoul, Korea, Republic of
New Zealand
Auckland Hospital
Auckland, New Zealand, 1023
Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan
China Medical University Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Taipei, Taiwan
National Taiwan University Hospital (NTUH)
Taipei, Taiwan
Taipei Veterans General Hospital (TPVGH)
Taipei, Taiwan
Sponsors and Collaborators
Australasian Gastro-Intestinal Trials Group
Canadian Cancer Trials Group
Academic and Community Cancer Research United
National Health and Medical Research Council, Australia
Investigators
Layout table for investigator information
Study Chair: Nick Pavlakis, Prof AGITG
Layout table for additonal information
Responsible Party: Australasian Gastro-Intestinal Trials Group
ClinicalTrials.gov Identifier: NCT02773524    
Other Study ID Numbers: AG0315OG
First Posted: May 16, 2016    Key Record Dates
Last Update Posted: January 13, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by Australasian Gastro-Intestinal Trials Group:
Metastatic
Locally recurrent
Oesophago-gastric junction
Stomach
Adenocarcinoma
Undifferentiated Carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases